

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

January 2017
Volume 20, Number 1

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – **New Programs:** Bendamustine with Rituximab for Previously Untreated CLL or SLL (ULYCLLFBR)
- **Cancer Drug Manual** – Acknowledgment of Editorial Board and Contributors
- **Benefit Drug List** – New: ULYCLLFBR
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts:** New: ULYCLLFBR; Revised: BRAVCLOD, GICOXB, UGIOCTLAR, GOOVDDCAT, GOOVETO, ULKCMLP, LUSCPI, LYCSPA, LYCVPPABO, MYBORMTN, MYBORREL, MYMPBOR, UMYLENDEX, SCPAINLI
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

The BCCA Provincial Systemic Therapy Program has approved the following new program effective 1 January 2017:

Lymphoma:

Bendamustine With Rituximab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (ULYCLLFBR) – Fludarabine-based chemotherapy is the standard first-line therapy for CLL and SLL. However, in patients who are not suitable for this intensive therapy, bendamustine with rituximab is now available as an alternative upfront treatment. A recently published phase III, randomized study (CLL10 Study) compared bendamustine and rituximab against fludarabine, cyclophosphamide and rituximab (FCR).¹ In this trial, the two treatment arms were equally effective in improving overall survival, but FCR demonstrated superior median progression free survival (55.2 mo vs. 41.7 mo). Bendamustine with rituximab was, however, better tolerated particularly in elderly patients over 65 years of age.

CANCER DRUG MANUAL

ACKNOWLEDGMENT OF CDM CONTRIBUTORS

The Cancer Drug Manual staff would like to acknowledge the contributions of the Editorial Board and the expert reviewers for their ongoing support of the Manual, and for generously sharing their time and expertise throughout the year.

Editorial Board	Expert Reviewers
<p><u>Physicians:</u> Angela Chan (Medical Oncologist, BCCA) Dave Fenton (Medical Oncologist, BCCA) Deepa Wadhwa (Medical Oncologist, BCCA) Jeff Davis (Pediatric Oncologist, BC Children's Hospital)</p> <p><u>Nurses:</u> Sylvi Baillie (BCCA-SAHCSI) Fran Topp (BCCA-VC) Karen Janes (BCCA-VC)</p> <p><u>Pharmacists:</u> Mandeep Bains (BCCA-VC) Dennis Jang (BCCA-VC) Sanna Pellatt (BCCA-VIC) Roberta Esau (BC Children's Hospital)</p>	<p><u>Physicians:</u> Luke Chen (Medical Oncologist, BCCA) Alina Gerrie (Medical Oncologist, BCCA) Bal Johal (Medical Oncologist, BCCA) Sanjay Rao (Medical Oncologist, BCCA) Kerry Savage (Medical Oncologist, BCCA) Laurie Sehn (Medical Oncologist, BCCA) Kevin Song (Medical Oncologist, BCCA) Anna Tinker (Medical Oncologist, BCCA)</p> <p><u>Pharmacists:</u> Jackie Buston (BCCA-VIC) James Conklin (BCCA-VC) Linda Hamata (BCCA-VC) Robert Tillmanns (BCCA-AC)</p>

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 1 January 2017, the following BCCA treatment program has been added to the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and ritUXimab	ULYCLLFBR	Restricted

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BCCA Compassionate Access Program approval are prefixed with the letter "U".

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
ULYCLLFBR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and ritUXimab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVCLOD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Reference to Class II deleted</i>	For Therapy of Bone Metastases in Breast Cancer Using Oral Clodronate
GICOXB	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reference to Class II deleted</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
UGIOCTLAR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dosing clarified</i>	Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract Using Octreotide
GOOVDDCAT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Size of filter specified</i>	Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using CARBOplatin and Weekly PACLitaxel
GOOVETO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Reference to Class II deleted</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Etoposide
ULKCMLP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Caution in elderly clarified</i>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Ponatinib
LUSCPI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reference to Class II deleted</i>	Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan with or without Platinum
LYCSPA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Reference to Class II deleted</i>	Cyclosporine for Cytopenias Associated with Lymphoproliferative Disorder of Large Granular Lymphocytes
LYCVPPABO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected in Baseline Tests</i>	Treatment of Hodgkin's Disease with Cyclophosphamide, vinBLASTine, Procarbazine and predniSONE
MYBORMTN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Reference to UMYBORREL deleted</i>	Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality
MYBORREL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol Code in footer corrected</i>	Treatment of Relapsed Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide
MYMPBOR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>CAP requirement for further treatment clarified</i>	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UMYLENEX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dosing for renal dysfunction clarified</i>	Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone
SCPAINLI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dosing interval updated</i>	Extreme Pain Therapy Using Parenteral Lidocaine

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	WWW.BCCANCER.BC.CA
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-Printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mario de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Lorraine Leitz, MLS
 Ava Hatcher, RN, BN CONc
 Rob Watt, BSc(Pharm)